Platelet reactivity in patients with chronic kidney disease undergoing percutaneous coronary intervention

References

• Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, Juni P, Kastrati A, Kolh PMauri L,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developedin collaboration with EACTS. Eur Heart J 2018;39:213-260. doi:10.1093/eurheartj/ehx419
   Google Scholar
• Go AS, Chertow GM, Fan D, McCulloch CE, Hsu C. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296–1305. doi: 10.1056/NEJMcp041956.
   PubMed Web of Science ®Google Scholar
• Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD. Use of evidence-based therapies in short-term outcomes of ST-segment elevation myocardial infarction and non – ST-segment elevation myocardial infarction in patients with chronic kidney disease. Circulation 2010;121:357–365. doi: 10.1161/CIRCULATIONAHA.109.865352.
   PubMed Web of Science ®Google Scholar
• Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJL, Mann JF. Chronic kidney disease and cardiovascular risk : epidemiology, mechanisms, and prevention. Lancet 2013;382:339–352. doi: 10.1016/S0140-6736(13)60595-4.
   PubMed Web of Science ®Google Scholar
• Romana D, Rios A, Carvalho G, Simões E Silva AC, Borges KBG, Dusse LMS. Hemostatic changes in patients with end stage renal disease undergoing hemodialysis. Clin Chim Acta 2010;411:135–139. doi: 10.1016/j.cca.2009.11.022.
   PubMed Web of Science ®Google Scholar
• Yang K, Du C, Wang X, Li F, Xu Y, Wang S. Uremic solute indoxyl sulfate-induced platelet hyperactivity contributes to CKD-associated thrombosis in mice. Blood 2017;129:2667–2679. doi: 10.1182/blood-2016-10-744060.
   PubMed Web of Science ®Google Scholar
• Nishi T, Ariyoshi N, Nakayama T, Fujimoto Y, Sugimoto K, Wakabayashi S, Hanaoka HKobayashi Y. Impact of chronic kidney disease on platelet inhibition of clopidogrel and prasugrelin Japanese patients. Journal Of Cardiology 2017;69(5):752-755. doi:10.1016/j.jjcc.2016.07.017
   PubMed Web of Science ®Google Scholar
• Mangiacapra F, Cavallari I, Barbato E, Gilard M, Laskar M, Borz B, Lafont A, Barbey C, Godin M, Tron C, et al. Impact of chronic kidney disease on platelet reactivity and outcomes of patients receiving clopidogrel and undergoing percutaneous coronary intervention. Am J Cardiol 2014;113(7):1124–1129. doi: 10.1016/j.amjcard.2013.09.033.
   PubMed Web of Science ®Google Scholar
• Barbieri L, Pergolini P, Verdoia M, Rolla R, Nardin M, Marino P, Bellomo G, Suryapranata H, De Luca G. Platelet reactivity in patients with impaired renal function receiving dual antiplatelet therapy with clopidogrel or ticagrelor. Vascul Pharmacol 2016;79:11–15. doi: 10.1016/j.vph.2015.10.006.
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013;3(1):1–163.
   Web of Science ®Google Scholar
• Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD. Third universal definition of myocardial infarction. Circulation 2007;116:2634–2653. doi: 10.1161/CIRCULATIONAHA.107.187397.
   PubMed Web of Science ®Google Scholar
• Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, et al. Standardized bleeding definitions for cardiovascular clinical trials: A consensus report from the bleeding academic research consortium. Circulation 2011;123(23):2736–2747. doi: 10.1161/CIRCULATIONAHA.110.009449.
   PubMed Web of Science ®Google Scholar
• Hobson AR, Petley GW, Dawkins KD, Curzen N. A novel fifteen minute test for assessment of individual time-dependent clotting responses to aspirin and clopidogrel using modified thrombelastography. Platelets 2007;18(7):497–505. doi: 10.1080/09537100701230436.
   PubMed Web of Science ®Google Scholar
• Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention. is the current antiplatelet therapy adequate? J Am Coll Cardiol 2007;49(6):657–666. doi: 10.1016/j.jacc.2006.10.050.
   PubMed Web of Science ®Google Scholar
• Baber U, Chandrasekhar J, Sartori S, Aquino M, Kini AS, Kapadia S, Weintraub W, Muhlestein JB, Vogel B, Faggioni M, et al. Associations between chronic kidney disease and outcomes with use of prasugrel versus clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention: aReport from the PROMETHEUS study. JACC Cardiovasc Interv 2017;10(20):2017–2025. doi: 10.1016/j.jcin.2017.02.047.
   PubMed Web of Science ®Google Scholar
• Melloni C, Cornel JH, Hafley G, Neely ML, Clemmensen P, Zamoryakhin D, Prabhakaran D, White HD, Fox KA, Ohman EM, et al. Impact of chronic kidney disease on long-term ischemic and bleeding outcomes in medically managed patients with acute coronary syndromes : insights from the TRILOGY ACS Trial. Eur Heart J Acute Cardiovasc Care 2016;5(6):443–454. doi: 10.1177/2048872615598631.
   PubMed Web of Science ®Google Scholar
• Jalal D, Chonchol M, Targher G. Disorders of hemostasis associated with chronic kidney disease. Semin Thromb Hemost 2010;36(1):34–40. doi: 10.1055/s-0030-1248722.
   PubMed Web of Science ®Google Scholar
• Tang YD, Wang WY, Yang M, Zhang K, Chen J, Qiao SB, Yan HB, Wu YJ, Huang XH, Xu B, et al. Randomized comparisons of 375 double- dose clopidogrel or adjunctive cilostazol versusstandard dual anti- platelet in patients with high post- treatment platelet reactivity: results of the CREATIVE trial. Circulation 2018;137 (6). doi:10.1161/CIRCULATIONAHA.117.031422.
   Google Scholar
• Muller C, Caillard S, Jesel L, El Ghannudi S, Ohlmann P, Sauleau E, Hannedouche T, Gachet C, Moulin B, Morel O. Association of estimated GFR with platelet inhibition in patients treated with clopidogrel. Am J Kidney Dis 2012;59(6):777–785. doi: 10.1053/j.ajkd.2011.12.027.
   PubMed Web of Science ®Google Scholar
• Guo LZ, Kim MH, Kim TH, Park JS, Jin E, Shim CH, Choi SY, Serebruany VL. Comparison of three tests to distinguish platelet reactivity in patients with renal impairment during dual antiplatelet therapy. Nephron 2016;132:191–197. doi: 10.1159/000444027.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, Bassi AK, Tantry US. Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING study. J Am Coll Cardiol 2005;46(10):1820–1826. doi: 10.1016/j.jacc.2005.07.041.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Navickas IA, Mahla E, Dichiara J, Suarez TA, Antonino MJ, Tantry US, Cohen E. Adenosine diphosphate-induced platelet-fibrin clot strength: A new thrombelastographic indicator of long-term poststenting ischemic events. Am Heart J 2010;160(2):346–354. doi: 10.1016/j.ahj.2010.05.034.
   PubMed Web of Science ®Google Scholar
• Tang XF, Han YL, Zhang JH, Zhang J-H, Wang J, Zhang Y, Xu B, Gao Z, Qiao S-B, Chen J, et al. Comparing of light transmittance aggregometry and modified thrombelastograph in predicting clinical outcomes in Chinese patients undergoing coronary stenting with clopidogrel. Chin Med J 2015;128(6):774–779. doi: 10.4103/0366-6999.152611.
   PubMed Web of Science ®Google Scholar
• Polzin A, Dannenberg L, Sansone R, Levkau B, Kelm M, Hohlfeld T, Zeus T. Antiplatelet effects of aspirin in chronic kidney disease patients. J Thromb Haemostcasis 2016;14:375–380. doi: 10.1111/jth.13211.
   PubMed Web of Science ®Google Scholar
• Breet NJ, de Jong C, Bos WJ, van Werkum J, Bouman H, Kelder J, Bergmeijer T, Zijlstra F, Hackeng C, Ten Berg J. The impact of renal function on platelet reactivity and clinical outcome in patients undergoing percutaneous coronary intervention with stenting. Thromb Haemost 2014;112(6):1174–1181. doi: 10.1160/th14-04-0302.
   PubMed Web of Science ®Google Scholar
• Morel O, El Ghannudi S, Jesel L, Radulescu B, Meyer N, Wiesel M-L, Caillard S, Campia U, Moulin B, Gachet C, et al. Cardiovascular mortality in chronic kidney disease patients undergoing percutaneous coronary intervention is mainly related to impaired P2Y 12 inhibition by clopidogrel. J Am Coll Cardiol 2011;57(4):399–408. doi: 10.1016/j.jacc.2010.09.032.
   PubMed Web of Science ®Google Scholar
• Baber U, Mehran R, Kirtane AJ, Gurbel PA, Christodoulidis G, Maehara A, Witzenbichler B, Weisz G, Rinaldi MJMetzger DC, et al. Prevalence and impact of high platelet reactivity in chronic kidney disease: results from the assessment of dual antiplatelet therapy with drug-eluting stents registry. Circ Cardiovasc Interv 2015;8(6):e001683. doi:10.1161/CIRCINTERVENTIONS.115.001683.
   PubMed Web of Science ®Google Scholar
• Mavrakanas TA, Alam A, Reny J, Smith JW, Kelton JG, Nazy I. Platelet reactivity in stable cardiovascular patients with chronic kidney disease disease. Platelets 2018;29(5):455–462. doi: 10.1080/09537104.2017.1378808.
   PubMed Web of Science ®Google Scholar
• Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ruven HJ, Bal ET, Deneer VH, Harmsze AM, van der Heyden JA, Rensing BJ, et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010;303(8):754-762. doi:10.1001/jama.2010.181.
   Google Scholar